



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/00	A2	(11) International Publication Number: WO 99/63978 (43) International Publication Date: 16 December 1999 (16.12.99)
<p>(21) International Application Number: PCT/US99/10534</p> <p>(22) International Filing Date: 12 May 1999 (12.05.99)</p> <p>(30) Priority Data: 09/094,058 9 June 1998 (09.06.98) US</p> <p>(71) Applicant (for all designated States except US): R.J. REYNOLDS TOBACCO COMPANY [US/US]; 950 Reynolds Boulevard, Winston-Salem, NC 27102 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): SUBBIAH, Ven [IN/US]; 105 Belle Vista Drive, Edenton, NC 27932 (US).</p> <p>(74) Agents: SAJOVEC, F., Michael et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>Without international search report and to be republished upon receipt of that report.</i></p>	
(54) Title: METHODS OF TREATING MICROBIAL INFECTION AND THERAPEUTIC FORMULATIONS THEREFOR		
<p>(57) Abstract</p> <p>Active compounds including sclareol-like and sclareolide-like compounds are useful in methods of treating a wide variety of conditions and disorders, including those disorders caused by microbial (e.g., fungal and bacterial) infections, as well as those conditions and disorders caused by other mechanisms (e.g., activation of the adenylyl cyclase system). Pharmaceutical and cosmetic formulations comprising these active compounds are also useful in treating these disorders. One disorder that may be treated by the methods and formulations of the present invention is acne.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHODS OF TREATING MICROBIAL INFECTION AND THERAPEUTIC FORMULATIONS THEREFOR

Field of the Invention

The invention relates to pharmaceutical formulations and cosmetic formulations useful for treating a wide variety of conditions and disorders, including formulations and methods for providing antimicrobial (e.g., antibacterial
5 and antifungal) treatment to subjects in need of such treatment.

Background of the Invention

Pathogenic microbes, including bacteria, fungi, protozoae, and viruses, have a profound effect on human health and well-being. In particular, bacterial
10 and fungal infections are known to cause myriad human disorders, ranging from systemic and life-threatening diseases such as tuberculosis and pneumonia, to localized, discomfort-causing and appearance-altering conditions such as acne. The identification of therapeutic compounds useful in the treatment of microbial infections of all severities and modalities is a long-standing and potentially never-
15 ending goal of medicine and pharmacology, made all the more difficult by the resistance of certain microbes to pharmaceutical inactivation. Certain anti-microbial agents are proposed in Hanson, *Nat. Prod. Rep.*, 13, 59-71 (1996); Banthorpe et al., *Phytochem.* 29(7), 2145-2148 (1990) ; and Ulubelen et al., *Phytochem.*, 36(4), 971-974 (1994). Dermatological infections and disorders, in
20 particular, may be contrary to effective treatment with pharmaceutical or cosmetic compounds in view of the barrier function of the skin and the difficulty of drug or cosmetic absorption thereby.

Although there are several factors that are thought to cause the skin disorder generally known as acne, one known causative factor is the presence of bacteria in the follicular canal of the skin. Within the follicular canal are bacteria which are indigenous to the follicular lining. One example of this bacteria is the anaerobic, gram positive *Propionibacterium acnes*. It is thought that *P. acnes* lives in symbiosis on the keratin lined follicular canal. *P. acnes* ingests the sebum produced from the sebocytes of the sebaceous glands. This nascent sebum is largely lipid in composition and also contains DNA, RNA, proteins, and other cellular components that result from the breakdown of sebocytes themselves. The *P. acnes* organisms, which are highly lipophilic, feed on the nascent sebum. It has been shown that *P. acnes* is found only in sebaceous-rich areas. If the nutrients increase due to an active and large sebaceous system, then colonization and high growth rates of *P. acnes* will occur. Resident bacterial flora will produce biologically active molecules such as histamine, extracellular enzymes, and peptides which may be responsible for the chemotaxis of the inflammatory infiltrate in acne vulgaris. Since the follicular lining in the pilosebaceous unit is intact, it has been theorized that if colonization of *P. acnes* occurs in sufficient numbers, they may produce initiating autogenic molecules that promote the initiating of inflammation. *P. acnes* can produce proteinases, lipase, and hyaluronate lyase all of which may serve as the catalysts or initiators of the inflammatory infiltrate, which has been shown to be composed of neutrophils and lymphocytes.

Gram negative acne, sometimes called gram negative folliculitis when it extends to the neck, arms, legs, and trunk, is a form of an inflammatory papular, follicular, and pustular response to gram negative organisms including *Enterobacter*, *Klebsiella*, *Escherichia*, *Proteus*, *Serratia*, and *Pseudomonas*. The most characteristic lesion on the face is superficial pustules, or papulo-pustules (which is a combination of a papule and pustule). The face can show diffuse erythema and inflammation surrounding these pustules and juicy papules or papulo-pustules. Gram negative acne is usually highly resistant and usually occurs in patients who have had inflammatory papular acne for long periods or who have been treated with long term oral administration of antibiotics such as tetracycline,

erythromycin, or minocycline or topical antibiotics such as topical clindamycin or topical erythromycin. Subsequent to the oral administration tetracycline or erythromycin, oral administration of amoxicillin, ampicillin, and trimethoprim-sulfomethoxazole has been shown to be effective in treating this disease. Poli, F.,
5 Prost, C., Revuz, J., *Gram-negative Folliculitis, Ann. Dermatol. Venereol.*,
115:797-800, 1988.

A number of topical and systemic therapeutic treatments are presently known for treating acne. Some of the topical treatments that are presently employed are: topical erythromycin, clindamycin, benzoyl peroxide, sulfur,
10 resorcinol, sulfosalicylate, salicylic acid, and retinoin (Retin-A[®]).

Benzoyl peroxide, $(C_6H_5CO)_2O_2$ ("BZP"), is a potent nontoxic oxidant which has long been used for treatment of dermatological lesions and known to be an effective anti-microbial and anti-keratolytic agent useful, for example, in the treatment of acne. Difficulties noted with BZP preparations have included BZP
15 chemical instability. In its particulate solid form, BZP has been found to be generally more stable than its dissolved form. However, when a preparation containing BZP particles is utilized to treat dermatological lesions, the BZP particles eventually contacting the skin may have adverse irritative effects. These adverse effects appear to result, at least in part, from the excessive concentrations
20 of BZP at skin areas in contact with BZP particles. Methods of avoiding such adverse effects while still effectively utilizing BZP therapeutically are long-sought. Still other topical treatments for acne using anti-bacterials are described in the following U.S. patents: an azole derivative in conjunction with benzoyl peroxide, U.S. Pat. No. 4,446,145, and metronidazole in a special gel as described in U.S.
25 Pat. No. 4,837,378.

Aside from treatments mentioned above, some additional systemic treatments for acne that are presently employed are: oral tetracycline; oral erythromycin; minocycline; doxycycline; oral trimethoprim-sulfamethoxazole and isotretinoin (ACCUTANE[®]).

30 It would be desirable to provide methods of providing antimicrobial (e.g., antibacterial and antifungal) treatment, as well as treatment for other conditions

and disorders caused by other mechanisms to subjects in need of such treatment, and cosmetic and pharmaceutical formulations useful in such treatments.

Summary of the Invention

5 The present invention provides methods and formulations (both cosmetic and pharmaceutical) useful in treating a wide variety of disorders and conditions, including those disorders and conditions caused by bacterial and fungal infection in humans and animals. The methods and formulations of the present invention are useful in treating undesirable conditions or disorders caused by, for example,
10 microorganisms selected from the group consisting of *Enterobacter aerogens*, *Propionibacterium acnes*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Bacillus subtilis*, *Agrobacterium tumefaciens*, *Staphylococcus aureus*, *Saccharomyces cerevisiae*, *Candida kefyr*, *Aspergillus flavus* and *Penicillium notatum*. The methods and formulations of the present invention are particularly useful in
15 treating undesirable skin conditions such as, for example, acne vulgaris, preadolescent acne, acne rosacea (now known as rosacea), premenstrual acne, acne venenata, acne cosmetica, pomade acne, acne detergentans, acne cosmetica, acne excoriee, gram negative acne, steroid acne, acne conglobata, or nodulocystic acne. The present invention can also be used for topically treating certain types of
20 dermatitis, e. g. perioral dermatitis, seborrheic dermatitis, gram negative folliculitis, sebaceous gland dysfunction, hidradenitis suppurativa, pseudofolliculitis barbae, folliculitis and dermatophyte infections (e.g., such as ringworm, athletes foot, and jock itch). Microbes present on the skin, particularly when allowed to proliferate in moist skin areas, are thought to be causes of
25 objectionable body odor. The prevention and amelioration of such objectionable body odor in those susceptible thereto is also an objective of the present invention.

 Accordingly, the present invention relates to a method of treating conditions and disorders caused by microbial infections, as well as other conditions and disorders caused by other mechanisms, in a subject in need of such treatment.
30 The method comprises administering to the subject an active compound of the present invention (i.e., a sclareol-like or a sclareolide-like compound), in an amount effective to treat the disorder. One embodiment of the present invention is

a method of treating a skin condition caused by a bacterial or fungal infection in a subject in need of such treatment, comprising contacting the skin of the subject with an effective amount of an active compound of the present invention, including sclareolide, sclareol, and the cosmetically acceptable analogs and salts thereof.

5 The compound may be provided to the subject in a cosmetic formulation, which formulations are also described herein as embodiments of the invention. Another embodiment of the invention involves a method of using a sclareolide-like compound to selectively activate second-messenger pathways that are involved in causing certain conditions and disorders, particularly those disorders and

10 conditions associated with activation of the adenylyl cyclase system.

Detailed Description of the Invention

The "active compounds of the present invention" include sclareol-like and sclareolide-like compounds. Sclareol-like compounds are diterpene compounds, and include, for example, sclareol, 13-episclareol, ferruginol, salvipisone,

15 aethopisome, neoclerodane, sagequinone, romulogarzone, ortho-benzoquinone, para-benzoquinone, and clariol. Other sclareol-like compounds include abietane and icetexane diterpenoids, languidulane diterpene, paryin and pimarine diterpenes, methylene quinone diterpenoids, manoyl norditerpenoids, multicaulin,

20 salvipimarone and primane diterpenoid. *See, for example*, the types of compounds set forth in Gonzalez et al., *Can. J. Chem.* 67(2), 208-212(1989); Eanthorpe et al., *Phytochem.* 29, 2145-2148 (1990); Kouzi et al., *Helv. Chim. Acta.* 73(8), 2157-2164 (1990); Abraham, *Phytochem.* 36(6) 1421-1424 (1994); Ulubelen et al. *Phytochem.* 36(4), 971-974 (1994); Hanson, *Nat. Prod. Rep.*, 13, 59-71 (1996) and

25 Topcu et al., *J. Nat. Prod.* 59, 734-737 (1996). Sclareolide-like compounds are fused-ring diterpene compounds that may be derived from sclareol by chemical or biological techniques known to those skilled in the art; and include, for example, sclareolide, ambrox, and wiedenol. *See, for example*, the types of compounds set forth in Hanson, *Nat. Prod. Rep.* 13, 59-71 (1996); Chackalamanni et al.,

30 *Tetrahedron Letters* 36, 5315-5318 (1995); Barrero et al., *Tetrahedron Letters* 35, 2945-2948 (1994); Martres et al. *Tetrahedron Letters* 34, 801-8084 (1993) and Barrero et al., *Tetrahedron* 49(5), 10405-10412 (1993). The active compounds

typically are cosmetically or pharmaceutically acceptable analogs, derivatives, or salts of sclareol or sclareolide. In the practice of the present invention, the active compounds may alternatively be substituted with alkyl (both unsaturated and saturated, and branched and unbranched, such as methyl, ethyl, or isopropyl), aryl, halogen, hydroxy, alkoxy, and amino groups, as will be apparent to those skilled in the art. Additionally, any of the active compounds of the present invention may be present as an optical isomer, or chiral compound, or as a mixture of optical isomers and chiral compounds.

Sclareol is an important bioactive diterpene obtained from clary sage (*Salvia sclarea L.*). This diterpene is not widely distributed and the most convenient sources are flower heads of clary sage plant. Sclareol is obtained by solvent extraction of clary sage. U.S. Patent No. 3,060,172 describes a process for the isolation of sclareol from clary sage. *See also*, U.S. Patent Application Serial Nos. 08/792,081, filed 31 January 1997, and 08/824,147, filed 25 March 1997, which applications are incorporated herein in their entirety by reference.

Sclareolide is prepared by either chemical oxidation followed by lactonization of sclareol or by biotransformation of sclareol using a yeast strain. Exemplary methods of producing sclareolide include those methods disclosed in U.S. Patent Nos. 5,525,728 to Schneider et al., U.S. Patent No. 5,247,100 to Gerke et al., and German Patent Application DE 3942358 to Gerke et al. Briefly, these processes use a ruthenium catalyst and an oxidation step to convert sclareol into a crude sclareolide product. Other exemplary methods of converting sclareol to sclareolide that are more commonly used include the biotransformation and fermentation methods described in U.S. Patent Nos. 4,970,163 and 5,212,078, both to Farhood et al. Sclareolide produced by these described methods is normally provided in wet or dry cake form, and is generally from about 90% to 95% pure. Sclareolide has also been reported to have therapeutic properties. *See*, PCT Application No. WO 06/00704 to Braquet et al. The disclosures of these patents setting forth methods of producing sclareolide from sclareol are incorporated herein by reference in their entirety.

The active compounds of the present invention have antimicrobial (e.g., antibacterial and antifungal) activity. These compounds are useful for the

treatment of conditions including, but not limited to, acne vulgaris, preadolescent acne, rosacea, premenstrual acne, acne venenata, acne cosmetica, pomade acne, acne detergentans, acne cosmetica, acne excorie, gram negative acne, steroid acne, acne conglobata, or nodulocystic acne. The present invention can also be used for
5 topically treating certain types of dermatitis, e. g. perioral dermatitis, seborrheic dermatitis, gram negative folliculitis, sebaceous gland dysfunction, hidradenitis suppurativa, pseudofolliculitis barbae, folliculitis and dermatophyte infections (e.g., such as ringworm, athletes foot, and jock itch). The compounds are also useful in methods of preventing or ameliorating undesirable body odor.

10 Sclareolide-like compounds (in particular, sclareolide) evaluated using the techniques described in Bencherif et al., *JPET* 279, 1413-1421 (1996) are determined to exhibit a profile for inhibition of human nicotinic receptor function similar to forskolin (which is well established as an activator of adenylyl cyclase).

Subjects to be treated by the methods of the present invention are typically
15 human subjects, although the methods of the present invention may be useful with any suitable subjects known to those skilled in the art, and particularly mammalian subjects including, in addition to humans, horses, cows, dogs, rabbits, fowl, sheep, and the like, for veterinary purposes.

The present invention provides cosmetic and pharmaceutical formulations
20 comprising the active compounds (including the pharmaceutically acceptable salts thereof), in pharmaceutically or cosmetically acceptable carriers for oral, rectal, topical, buccal, parenteral, intramuscular, intradermal, or intravenous, and transdermal administration. In a preferred embodiment of the invention, the active compound may be administered to the subject as a topical, cosmetic formulation
25 comprising (a) an active compound of the present invention and (b) a cosmetically acceptable carrier. The active compounds may be formulated for administration as cosmetic formulations for the treatment of a variety of conditions. These cosmetic formulations may take the form of, for example, a liquid, lotion, aerosol, cream, gel or ointments. In a preferred embodiment of a method of the present invention,
30 an active compound of the present invention or a pharmaceutical or cosmetic formulation comprising the active compound is contacted with the skin of a subject suffering from a skin disorder caused by bacterial or fungal infection.

In the manufacture of a pharmaceutical or cosmetic formulation according to the invention, the active compounds (including the physiologically acceptable salts thereof) are typically admixed with, *inter alia*, an acceptable carrier. The carrier must, of course, be acceptable in the sense of being compatible with any other ingredients in the formulation and must not be deleterious to the patient. The carrier may be a solid or a liquid, or both, and is preferably formulated with the compound as a unit-dose formulation, for example, a tablet, which may contain from 0.5% to 95% by weight of the active compound. One or more active compounds may be incorporated in the formulations of the invention, which may be prepared by any of the well known techniques of pharmacy consisting essentially of admixing the components, optionally including one or more accessory ingredients.

The formulations of the invention include those suitable for oral, rectal, topical, buccal (e.g., sub-lingual), parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) and transdermal administration, although the most suitable route in any given case will depend on the nature and severity of the condition being treated and on the nature of the particular active compound which is being used.

Formulations suitable for oral administration may be presented in discrete units, such as capsules, cachets, lozenges, or tablets, each containing a predetermined amount of the active compound; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water or water-in-oil emulsion. Such formulations may be prepared by any suitable method of pharmacy which includes the step of bringing into association the active compound and a suitable carrier (which may contain one or more accessory ingredients as noted above). In general, the formulations of the invention are prepared by uniformly and intimately admixing the active compound with a liquid or finely divided solid carrier, or both, and then, if necessary, shaping the resulting mixture. For example, a tablet may be prepared by compressing or molding a powder or granules containing the active compound, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing, in a suitable apparatus, the compound in a free-flowing form, such as a powder or

granules optionally mixed with a binder, lubricant, inert diluent, and/or surface active/dispersing agent(s). Molded tablets may be made by molding, in a suitable apparatus, the powdered compound moistened with an inert liquid binder.

Formulations suitable for buccal (sub-lingual) administration include
5 lozenges comprising the active compound in a flavored base, usually sucrose and acacia or tragacanth; and pastilles comprising the compound in an inert base such as gelatin and glycerin or sucrose and acacia.

Formulations of the present invention suitable for parenteral administration conveniently comprise sterile aqueous preparations of the active compound, which
10 preparations are preferably isotonic with the blood of the intended recipient. These preparations may be administered by means of subcutaneous, intravenous, intramuscular, or intradermal injection. Such preparations may conveniently be prepared by admixing the compound with water or a glycine buffer and rendering the resulting solution sterile and isotonic with the blood.

Formulations suitable for rectal administration are preferably presented as
15 unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.

Formulations suitable for transdermal administration may be presented as
20 discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Formulations suitable for transdermal administration may also be delivered by iontophoresis (*see*, for example, *Pharmaceutical Research* 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. Suitable
25 formulations comprise citrate or bis/tris buffer (pH 6) or ethanol/water and contain from 0.1 to 0.2M active ingredient.

Topical cosmetic formulations suitable for topical application to the skin are particularly preferred, and may take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, lotion, shampoo, foam, cream, gel, ointment, salve, milk,
30 stick, spray, balm, emulsion, powder, solid or liquid soap, or oil. Such topical formulations comprise the active compound and a cosmetically acceptable carrier or medium. The cosmetically acceptable carrier generally comprises water or of a

mixture of water and at least one organic solvent which is physiologically acceptable for the purpose of a topical application. Among these solvents, exemplary are acetone, C₁-C₄ lower alcohols such as ethanol and isopropyl alcohol, alkylene glycols such as ethylene glycol and propylene glycol, ethylene glycol monomethyl, monoethyl or monobutyl ethers, the monoethyl ethers of propylene glycol and of dipropylene glycol, the C₁-C₄ alkyl esters of short-chain acids and polytetrahydrofuran ethers. When these are indeed present, such solvents preferably constitute from 1% to 80% by weight of the total weight of the formulation.

10 Depending on the intended application of the subject formulations, one skilled in the art can easily select the particular compounds and adjuvants that are necessary and characteristically employed to prepare those formulations. Among these adjuvants or additives, especially representative are preservatives, stabilizing agents, pH regulators, osmotic pressure modifiers, emulsifying agents, sunscreen agents, antioxidants, fragrances, colorants, anionic, cationic, nonionic, amphoteric
15 or zwitterionic surface-active agents or mixtures thereof, polymers, and the like.

- A topical formulation of the present invention, in addition to the active compound or the pharmaceutically acceptable salt thereof and the cosmetically acceptable medium or carrier, may also include an agent which enhances
20 penetration of an active ingredient through the skin. Exemplary agents which increase skin penetration are disclosed in the following U.S. patents all of which are incorporated herein by reference: U.S. Pat. No. 4,537,776 (a binary combination of N-(hydroxyethyl)pyrrolidone and a cell-envelope disordering compound); U.S. Pat. No. 4,130,667 (using a sugar ester in combination with a
25 sulfoxide or phosphine oxide); and U.S. Pat. No. 3,952,099 (using sucrose monooleate, decyl methyl sulfoxide, and alcohol). *See also* Manou et al., *Acta Horticulture* 344, 361-69 (1993).

Other exemplary materials that increase skin penetration are surfactants or wetting agents which include the following: polyoxyethylene sorbitan mono-
30 oleate (Polysorbate 80); sorbitan monooleate (Span 80); p-isooctyl polyoxyethylene-phenol polymer (Triton WR-1330); polyoxyethylene sorbitan tri-

oleate (Tween 85); dioctyl sodium sulphosuccinate; and sodium sarcosinate (Sarcosyl NL-97); and other pharmaceutically acceptable surfactants.

The pharmaceutically or cosmetically acceptable carrier may be thickened using thickening agents typically employed in cosmetics or in pharmaceuticals.

5 Among these thickening agents, particularly exemplary are cellulose and derivatives thereof such as cellulose ethers, heterobiopolysaccharides such as xanthan gum, scleroglucans, and polyacrylic acids which either may or may not be cross-linked. The thickening agents are preferably present in proportions ranging from 0.1% to 5% by weight approximately relative to the total weight of the
10 composition.

The dose of the compound administered to the subject in need of treatment is that amount effective to prevent the onset or occurrence of a disorder caused by microbial infection, or to treat the disorder caused by the microbial infection from which the subject suffers. By "effective amount," "therapeutic amount," or
15 "effective dose," is meant that amount sufficient to elicit the desired pharmacological or cosmetic effects, thus resulting in effective prevention or treatment of the disorder.

Preferably, the purity of the active compounds of the present invention is greater than about 50% pure, usually greater than about 80% pure, often greater
20 than about 90% pure, and more often greater than about 95%, 98%, or even 99% pure, with active compounds approaching 100% purity being used most often.

The effective concentration or dosage of any specific compound, the use of which is in the scope of present invention, will vary somewhat from compound to compound, patient to patient, and will depend upon the condition of the patient and
25 the route of delivery. As a general proposition, the dosage of an active compound of the present invention at which therapeutic efficacy will be achieved may be low as about 10 mg/kg, but is often greater than 25 or 50 mg/kg, and typically greater than about 100 mg/kg. The dosage of the active compound may be as high as about 5000 mg/kg, but is typically less than about 1000 mg/kg, usually less than
30 750 mg/kg and frequently less than 500 mg/kg. Still higher dosages may potentially being employed for oral, topical, and/or aerosol administration. Toxicity concerns at the higher level may restrict intravenous dosages to a lower

level such as up to about 100 mg/kg, all weights being calculated based upon the weight of the active base, including the cases where a salt is employed. Typically a dosage from about 10 mg/kg to about 50 mg/kg will be employed for intravenous or intramuscular administration. A dosage from about 10 mg/kg to about 50 mg/kg may be employed for oral administration. For topical administration, suitable concentrations of the active compound may be from 1000 mg/ml to about 5000 mg/ml.

Active compounds used in the present method of treating microbial infections may be administered in conjunction with another antimicrobial agent, such other anti-acne agents including, but not limited to, benzoyl peroxide.

The preferred regime or regimen of application comprises applying 1 g to 10 g of the composition to all or to certain parts of the skin, at a frequency of one to two applications per day, for 1 to 7 days per week, for a period of time of from 1 to 6 months or even longer.

The present invention is further illustrated by the following non-limiting experimental examples.

EXAMPLE 1

Evaluation of antibacterial properties of sclareol and sclareolide

The following seven bacteria were grown on nutrient agar slants for 48 hours at 37° C: *Enterobacter aerogens*, *Propionibacterium acnes*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Bacillus subtilis*, *Agrobacterium tumefaciens*, and *Staphylococcus aureus*.

A bacterial colony from each of the respective slants was suspended in 1 ml sterile deionized water. 0.1 ml of each cell suspension was evenly spread on nutrient agar plates (10×10^5 cells/ml). After 30 min, sclareol and sclareolide-impregnated disks were placed on bacteria-lawned plates. The sclareol and sclareolide used in this experiment were relatively pure samples (greater than 99% pure). Triplicate disks of (10, 100, 500, and 1000 ug/disk) of each sample was applied on to 6 mm diameter (0.3 mm thickness) filter paper disks and air dried. Controls were prepared with respective solvents. Plates were incubated for 24-48

hr at 37°C. The inhibition zones were measured and recorded after 15 hr, up to 48 hr.

The results of this experiment are summarized in Table 1, below. In general, sclareol was more active than sclareolide against the bacteria tested. The bacteria *P. acnes*, *S. aureus* and *E. aerogens* were found to be more sensitive to both sclareol and sclareolide treatment, while *P. aeruginosa* and *E. coli* were the least sensitive to both compounds. Both compounds were found to be more active against Gram positive bacteria, specifically, *S. aureus* and *P. acnes*.

10 Table 1. Effect of sclareol and sclareolide on selected bacterial cultures

		Zone of inhibition							
		Sclareol (ug/disk)				Sclareolide (ug/disk)			
		10	100	500	1000	10	100	500	1000
15	<i>E. aerogens</i>	+	+++	+++	+++	+	++	+++	+++
	<i>P. acnes</i>	+	+++	+++	+++	+	+++	+++	+++
	<i>P. aeruginosa</i>	-	+	++	++	-	-	++	++
	<i>E. coli</i>	-	-	+	++	-	-	+	++
	<i>B. subtilis</i>	+	+	++	++	+	+	+	++
	<i>A. tumefaciens</i>	+	++	+++	+++	+	++	+++	+++
20	<i>S. aureus</i>	+	++	+++	+++	+	++	+++	+++

Legend for Table 1: +++ - High inhibition; ++ - moderate inhibition; + - low inhibition; - - non inhibition.

The results from these experiments illustrate that the active compounds of the present invention are effective in inhibiting bacteria associated with numerous human diseases, thereby demonstrating the effectiveness of administration of the active compounds of the present invention as a treatment for these diseases.

EXAMPLE 2

30 Antifungal properties of sclareol and sclareolide

The yeast and fungi listed below in Table 2 were grown on potato dextrose agar (PDA) containing different concentrations of sclareol and sclareolide, according to the following method: sclareol or sclareolide (in powder form) was added to pre-measured amounts of PDA medium in petri plates, mixed thoroughly by tilting the petri plate from side to side, and allowed to solidify. The sclareol and

sclareol used in preparing the petri plates was of greater than 99% purity. After solidification, the plates were inoculated with 5 mm disks, cut from the outer margin of the actively growing cultures of yeast and fungi and placed in the center of the plate in an inverted position in direct contact with the sclareol/sclareolide impregnated medium. The plates were incubated at 26° C. The plates were
 5 monitored periodically to estimate the minimum inhibitory concentration (MIC) based on the growth proliferation from the 5mm inoculum disk.

The results were measured and recorded after 48 hr, up to one week. The results are tabulated in Table 2, below.

10

Table 2. Antifungal properties of sclareol and sclareolide on selected yeast and fungi

Microorganism	MIC (ug/ml)	
	Sclareol	Sclareolide
<i>Saccharomyces cerevisiae</i>	500	500
<i>Candida kefyri</i>	100	400
<i>Aspergillus flavus</i>	1000	1000
<i>Penicillium notatum</i>	1000	1000

15 The results from this experiment illustrate that the active compounds of the present invention are effective in inhibiting the growth of fungi associated with certain human diseases or disorders, thereby demonstrating the effectiveness of administration of the active compounds of the present invention as a treatment for these diseases.

20

EXAMPLE 3

SUMMARY OF RESULTS

A summary of the effects of sclareol and sclareolide against the bacteria
 25 and fungi tested in Examples 1 and 2 is provided in Table 3. The data is presented as the effect of sclareol and sclareolide on selected microbial cultures, in terms of minimum inhibitory concentration, as measured in µg/ml.

Table 3: Effect of Sclareol and Sclareolide on selected microbial cultures

	Microbe	MIC (ug/ml)	
		Sclareol	Sclareolide
5			
	<i>E. aerogens</i>	10	10
	<i>P. acnes</i>	40	40
	<i>P. aeruginosa</i>	100	500
	<i>E. coli</i>	500	500
10	<i>B. subtilis</i>	10	10
	<i>A. tumefaciens</i>	10	10
	<i>S. aureus</i>	50	50
	<i>Saccharomyces</i>	500	500
	<i>Candida kefyr</i>	100	400
15	<i>Aspergillus flavus</i>	1000	1000
	<i>Penicillium notatum</i>	1000	1000

In the specification and examples, there have been disclosed preferred
embodiments of the invention. Although specific terms are employed in these
20 examples, they are used in a generic and descriptive sense only and not for the
purpose of limitation, the scope of the invention being defined by the following
claims and their equivalents.

THAT WHICH IS CLAIMED:

1. A method of treating a disorder caused by a microbial infection in a subject in need of such treatment, comprising administering a sclareol-like or a sclareolide-like compound to said subject, in an amount effective to treat the disorder.
2. A method according to Claim 1, wherein the disorder caused by a microbial infection is caused by an organism selected from the group consisting of *Enterobacter aerogens*, *Propionibacterium acnes*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Bacillus subtilis*, *Agrobacterium tumefaciens*, *Staphylococcus aureus*, *Saccharomyces cerevisiae*, *Candida kefir*, *Aspergillus flavus* and *Penicillium notatum*.
3. A method according to Claim 2, wherein said microbial infection is caused by *Propionibacterium acnes*.
4. A method according to Claim 1, wherein said disorder is a skin disorder.
5. A method according to Claim 1, wherein said disorder is acne.
6. A method according to Claim 1, wherein said sclareol-like or sclareolide-like compound is topically administered to the skin of said subject.
7. A method according to Claim 6, comprising the additional step of topically administering benzoyl peroxide to the subject in need of such treatment.
8. A method according to Claim 1, wherein said sclareol-like compound is sclareol.

9. A method according to Claim 1, wherein said sclareolide-like compound is sclareolide.
10. A method according to Claim 1, wherein said sclareol-like or sclareolide-like compound is greater than about 90% pure.
11. A method according to Claim 1, wherein said sclareol-like or sclareolide-like compound is greater than about 95% pure.
12. A cosmetic formulation for treating a skin disorder caused by a microbial infection, comprising sclareol or a sclareolide-like compound in an amount sufficient to treat said skin disorder, in a cosmetically-acceptable carrier.
13. A cosmetic formulation according to Claim 12, wherein said sclareol-like compound is sclareol.
14. - A cosmetic formulation according to Claim 12, wherein said sclareolide-like compound is sclareolide.
15. A cosmetic formulation according to Claim 12, wherein said cosmetic formulation is a cream.
16. A cosmetic formulation according to Claim 12, wherein said formulation is a lotion.
17. A method of treating a condition or disorder associated with activation of a second messenger pathway in a subject in need of such treatment, the method comprising administering a sclareolide-like compound to said subject in an amount effective to treat the disorder.
18. A method according to Claim 17, wherein said second messenger pathway is the adenylyl cyclase system.

19. A method according to Claim 17, wherein said sclareolide-like compound is sclareolide.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/365, 31/045	A3	(11) International Publication Number: WO 99/63978 (43) International Publication Date: 16 December 1999 (16.12.99)
<p>(21) International Application Number: PCT/US99/10534</p> <p>(22) International Filing Date: 12 May 1999 (12.05.99)</p> <p>(30) Priority Data: 09/094,058 9 June 1998 (09.06.98) US</p> <p>(71) Applicant (for all designated States except US): R.J. REYNOLDS TOBACCO COMPANY [US/US]; 950 Reynolds Boulevard, Winston-Salem, NC 27102 (US).</p> <p>(72) Inventor; and (75) Inventor/Applicant (for US only): SUBBIAH, Ven [IN/US]; 105 Belle Vista Drive, Edenton, NC 27932 (US).</p> <p>(74) Agents: SAJOVEC, F., Michael et al.; Myers, Bigel, Sibley, & Sajovec, P.A., P.O. Box 37428, Raleigh, NC 27627 (US).</p>	<p>(81) Designated States: AE, AL, AM, AT, AT (Utility model), AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ (Utility model), DE, DE (Utility model), DK, DK (Utility model), EE, EE (Utility model), ES, FI, FI (Utility model), GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (Utility model), SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 13 April 2000 (13.04.00)</p>	
(54) Title: METHODS OF TREATING MICROBIAL INFECTION AND THERAPEUTIC FORMULATIONS THEREFOR		
<p>(57) Abstract</p> <p>Active compounds including sclareol-like and sclareolide-like compounds are useful in methods of treating a wide variety of conditions and disorders, including those disorders caused by microbial (e.g., fungal and bacterial) infections, as well as those conditions and disorders caused by other mechanisms (e.g., activation of the adenylyl cyclase system). Pharmaceutical and cosmetic formulations comprising these active compounds are also useful in treating these disorders. One disorder that may be treated by the methods and formulations of the present invention is acne.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/10534

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/365 A61K31/045

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE WPI Week 9907 Derwent Publications Ltd., London, GB; AN 99-073874 XP002118286 & JP 10 298070 A (TOA GOSEI CHEM IND LTD), 10 November 1998 (1998-11-10) abstract	1,2,8
P,X	--- DEMETZOS C ET AL: "Chemical analysis and antimicrobial activity of the resin Ladano, of its essential oil and of the isolated compounds [letter]" PLANTA MED, FEB 1999, 65 (1) P76-8, XP002118269 GERMANY the whole document ---	1,2,8, 10-13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

18 October 1999

Date of mailing of the international search report

21.02.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

MAIR J.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 99/10534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 9005 Derwent Publications Ltd., London, GB; AN 90-033362 XP002118287 & JP 01 311018 A (SHISEIDO CO LTD), 15 December 1989 (1989-12-15) abstract	1-6,12, 15,16
X	--- ULUBELN, A. ET AL: "Terpenoids from Salvia sclarea" PHYTOCHEMISTRY, vol. 36, no. 4, 1994, pages 971-974, XP002118270 cited in the application the whole document especially page 973, table 2	1,2,8
X	--- BANTHORPE, D.V. ET AL: "Accumulation of the anti-fungal diterpene sclareol by cell cultures of Salvia sclarea and Nicotiana glutinosa" PHYTOCHEMISTRY, vol. 29, no. 7, 1990, pages 2145-2148, XP000671796 cited in the application the whole document	1,8
X	--- KOUZI, S.A. ET AL: "Microbial metabolism of the diterpene sclareol: oxidation of the A ring by Septomyxa affinis" HELVETICA CHIMICA ACTA, vol. 73, no. 8, 1990, pages 1257-2164, XP002118271 cited in the application the whole document	1,8
X	--- GONZALEZ, A.G. ET AL: "Abietane diterpenes with antibiotic activity from the flowers of Salvia canariensis. Reaction of galdosol with diazomethane" CANADIAN JOURNAL OF CHEMISTRY, vol. 67, no. 2, 1989, pages 208-212, XP002118272 cited in the application the whole document especially page 211, righthand column, line 6	1,2
	--- -/--	

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/US 99/10534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE DISSERTATION ABSTRACTS [Online] ACCESSION NUMBER: 01195651, XP002118284 abstract & DENTALI, S.J.: "Potential antiinfective agents from Eriodicyton angustifolium Nutt. and Salvia apiana Jeps." DISSERTATION ABSTRACTS INTERNATIONAL, vol. 52, no. 07-B, 1991, page 3616 ---	1,2
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US ACCESSION NUMBER: 102:21171, XP002118285 abstract & ASAHI, M. ET AL: "Antifungal activity of diterpenes isolated from Metasequoia glyptostroboides" NIPPON NOGEI KAGAKU KAISHI, vol. 58, no. 9, 1984, pages 887-889, ---	1
X	WO 90 14764 A (STEPHEN HERMAN) 13 December 1990 (1990-12-13) page 8, line 2-9 page 11, line 15-29 page 15, line 5-9 ---	1,4,6, 10-12, 15,16
X	EP 0 747 048 A (KABUSHIKI KAISHA YAKURIGAKU CHUO) 11 December 1996 (1996-12-11) page 3 page 13; example 9 ---	1,4-6, 10-12, 15,16
X	ULUBELEN, A. ET AL: "Terpenoids from Salvia palaestina" PHYTOCHEMISTRY, vol. 24, 1985, pages 1386-1387, XP002118273 the whole document ---	1,2,8, 10-13
X	ULUBELEN A ET AL: "Norditerpenoids and diterpenoids from Salvia multicaulis with antituberculous activity." J NAT PROD, DEC 1997, 60 (12) P1275-80, XP002118274 UNITED STATES the whole document especially page 1279, table 6 ---	1,2, 10-12

-/--

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/10534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHINO, I. ET AL: "Cytotoxic and antibacterial labdane-type diterpenes from the aerial parts of <i>Cistus incanus</i> subsp. <i>creticus</i> " PLANTA MED., 1994, 60, 34-6, XP002118275 the whole document especially page 35, table 1 ---	1,2,8, 10-13
X	DELLAR JE ET AL: "Unusual antimicrobial compounds from <i>Aeollanthus buchnerianus</i> ." EXPERIENTIA, FEB 15 1996, 52 (2) P175-9, XP002118276 SWITZERLAND page 179; table 4 ---	1,2, 10-12
X	BATISTA O ET AL: "Structure and antimicrobial activity of diterpenes from the roots of <i>Plectranthus hereroensis</i> ." J NAT PROD, JUN 1994, 57 (6) P858-61, XP002118277 UNITED STATES the whole document ---	1,2, 10-12
X	CAPSONI F ET AL: "Effect of ambroxol on human phagocytic cell function." BOLL IST SIEROTER MILAN, 1985, 64 (3) P236-9, XP002118278 ITALY the whole document ---	1,2,10, 11
X	PETRI G ET AL: "TANNINS AND OTHER POLYPHENOLIC COMPOUNDS IN THE GENUS <i>SALVIA</i> " 36TH ANNUAL CONGRESS ON MEDICINAL PLANT RESEARCH, FREIBURG, WEST GERMANY, SEPTEMBER 12-16, 1988, vol. 54, no. 6, 1988, page 575 XP002118279 the whole document ---	1,2,8-12
X	KALPOUTZAKIS, ELEFThERIOS ET AL: "Antibacterial labdane-type diterpenes from the resin "ladano" of <i>Cistus creticus</i> subsp. <i>creticus</i> " NAT. PROD. LETT., 1998, 11, 173-179, XP002118280 the whole document ---	1,2, 10-12
X	SAN-MARTIN, AURELIO ET AL: "Labdane diterpenes from the marine pulmonate gastropod <i>Trimusculus peruvianus</i> " CAN. J. CHEM., 1996, 74, 2471-2475, XP002118281 page 2474; table 3 --- -/--	1,2, 10-12

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/US 99/10534

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	IWAGAWA, TETSUO ET AL: "Gomojosides, labdane diterpenoids from Viburnum suspensum" PHYTOCHEMISTRY, 1992, 31, 1311-15, XP002118282 page 1312, right-hand column, line 27-32 ---	1,2, 10-12
A	JAMES R. HANSON: "Diterpenoids" NATURAL PRODUCT PRODUCTS, vol. 13, 1996, pages 59-71, XP002118283 cited in the application the whole document -----	1-16

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/10534

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-11
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-16

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1. Claims: 1-16

The use of "a sclareol-like or sclareolide-like compound" related to the treatment of microbial infections.

2. Claims: 17-19

The use of a "sclareolide-like compound" related to the treatment of conditions or disorders associated with activation of a second messenger pathway.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Further defects under Article 17(2)(a):

Continuation of Box 3.

The expression "a sclareol-like or a sclareolide-like compound" is not a clear and limited description of a chemical compound, because it is not possible to determine which compounds do or do not fall within this definition. Because of the use of this open-ended expression, present claims 1-7, 10-12, 15 and 16 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds sclareol and sclareolide and those compounds, for which references could be retrieved, mentioned in the description, page 5, line 15-20. Some of the compound names listed in the description (page 5, line 15-20) could not be retrieved, such as paryin diterpene, clariol and it is not known what is meant by others such as ortho-benzoquinone and methylene quinone diterpenoid. In view of this, a comprehensive search could not be performed.

Furthermore, although claims 12-16 are directed to cosmetic compositions, their use for the treatment of a skin disorder caused by a microbial infection is undoubtedly a therapeutic application. Consequently these must be pharmaceutical rather than cosmetic compositions. The search has been based on this assumption.

INTERNATIONAL SEARCH REPORT

Information on patent family members

National Application No

/US 99/10534

Patent document cited in search report	A	Publication date	Patent family member(s)	Publication date
JP 10298070	A	10-11-1998	NONE	
JP 1311018	A	15-12-1989	JP 2700070	B 19-01-1998
WO 9014764	A	13-12-1990	US 4983637	A 08-01-1991
			AU 627908	B 03-09-1992
			AU 5922590	A 07-01-1991
			CA 2060316	A 09-12-1990
			EP 0476054	A 25-03-1992
			JP 4506214	T 29-10-1992
			US 5086076	A 04-02-1992
			US 5126376	A 30-06-1992
			US 5190977	A 02-03-1993
			US 5270344	A 14-12-1993
			US 5260342	A 09-11-1993
EP 747048	A	11-12-1996	JP 8333272	A 17-12-1996
			JP 2838069	B 16-12-1998
			JP 9235221	A 09-09-1997
			CA 2178528	A 10-12-1996
			DE 747048	T 30-04-1997
			US 5773005	A 30-06-1998